BackDermata Therapeutics- Warrants (13/08/2026) Overview

Dermata Therapeutics- Warrants (13/08/2026) Total Assets

Latest total assets for DRMAW: $7.5M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$7.47M
25.38% YoYΔ $-2.54M vs prior year quarter

Peer average

Loading

Dermata Therapeutics- Warrants (13/08/2026) Total Assets History

Loading

Dermata Therapeutics- Warrants (13/08/2026) vs. peers: Total Assets Comparison

Loading

Dermata Therapeutics- Warrants (13/08/2026) Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Dermata Therapeutics- Warrants (13/08/2026) (DRMAW) FAQ

Dermata Therapeutics- Warrants (13/08/2026)'s total assets stands at $7.5M as of March 2026. That compares with $10M in the prior-year period — down 25.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Dermata Therapeutics- Warrants (13/08/2026) reported $7.5M in total assets versus $10M a year earlier — a 25.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $10M in the prior-year period — down 25.4% year over year. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Dermata Therapeutics- Warrants (13/08/2026)'s total assets evolved across reporting periods, while the comparison chart places DRMAW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total assets is commonly used to spot outliers. Dermata Therapeutics- Warrants (13/08/2026)'s reading of $7.5M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.